首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   126424篇
  免费   11397篇
  国内免费   6502篇
医药卫生   144323篇
  2024年   146篇
  2023年   1543篇
  2022年   2534篇
  2021年   5153篇
  2020年   3996篇
  2019年   3651篇
  2018年   3926篇
  2017年   3695篇
  2016年   3284篇
  2015年   5213篇
  2014年   6725篇
  2013年   6941篇
  2012年   10121篇
  2011年   10871篇
  2010年   7487篇
  2009年   6148篇
  2008年   7789篇
  2007年   7730篇
  2006年   7320篇
  2005年   6688篇
  2004年   4843篇
  2003年   4404篇
  2002年   3647篇
  2001年   3089篇
  2000年   2846篇
  1999年   2641篇
  1998年   1308篇
  1997年   1208篇
  1996年   944篇
  1995年   951篇
  1994年   881篇
  1993年   504篇
  1992年   890篇
  1991年   802篇
  1990年   670篇
  1989年   568篇
  1988年   524篇
  1987年   441篇
  1986年   356篇
  1985年   283篇
  1984年   184篇
  1983年   167篇
  1982年   95篇
  1981年   92篇
  1979年   140篇
  1978年   111篇
  1977年   83篇
  1974年   94篇
  1973年   72篇
  1972年   87篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients.  相似文献   
63.
64.
目的:评价电针深刺八髎穴治疗压力性尿失禁的疗效.方法:将60例压力性尿失禁的女性患者按就诊先后顺序分为两组,每组30例.对照组给予盆底肌训练,治疗组给予电针深刺八髎穴(上髎、次髎、中髎和下髎).结果:治疗组总有效率为93.3%,对照组为33.3%,治疗组的总有效率明显高于对照组(P<0.05).治疗后,两组国际尿失禁咨询委员会尿失禁问卷表简表(ICIQ-SF)评分及漏尿量均低于治疗前(均P<0.05),治疗组ICIQ-SF评分及漏尿量均低于对照组(均P<0.05).结论:长针深刺八髎穴能改善压力性尿失禁女性临床症状,疗效优于盆底肌训练.  相似文献   
65.
刘林  李修红 《现代肿瘤医学》2020,(14):2443-2447
目的:肌少症对老年肝癌术后恢复及预后的影响。方法:选取2015年1月至2017年12月收治的114例老年肝癌,根据有无合并肌少症,分为肌少症组(n=35)和非肌少症组(n=79)。比较两组患者的术后恢复及生存情况。结果:肌少症组总并发症发生率、住院时间和30 d再入院率均高于对照组,差异均有统计学意义(P<0.05)。肌少症组中位生存时间为25.9个月,1年、2年、3年累积总生存率为74.3%、51.1%、24.5%,而非肌少症组中位生存时间为35.7个月,1年、2年、3年累积总生存率为87.3%、75.6%、49.4%,差异有统计学意义(P=0.004)。单因素分析结果显示,老年肝癌术后预后与Charlson合并症指数(CCI)、肌少症、巴塞罗那分期(BCLC)、甲胎蛋白、肿瘤大小、肿瘤个数、肿瘤分化程度、微血管侵犯(MVI)相关(P<0.05)。Cox多因素分析结果显示,CCI、肌少症、BCLC分期、肿瘤个数、MVI是老年肝癌术后预后的独立危险因素(P<0.05)。结论:肌少症会增加老年肝癌患者术后并发症发生率,延长住院时间,影响术后恢复,同时也会降低总生存率。  相似文献   
66.
ABSTRACT

Most senior veterans who live in veteran homes in Taiwan have few interpersonal relationships. Aging is often accompanied by solitude and illness, which causes senior veterans to doubt the meaning of life and to lose confidence in the value of life. This study tested the effectiveness of a group reminiscence therapy protocol on the depression and meaning of life among elderly institutionalized veterans. A quasi-experimental design was applied. A convenience sample of older adults was drawn from two veteran homes in southern Taiwan. Participants were assigned to intervention or control groups based on the veterans' homes they attended. The participants in the intervention group carried out group reminiscence therapy for 8 weeks in addition to their daily activities. The participants in the comparison group maintained their daily activities. Both groups were evaluated using the GDS-SF and MLS scale including two aspects of depression mood and meaning of life in weeks 1 and 8. The overall life satisfaction increased significantly over time for the intervention group compared to the comparison group from week 1 to week 8. The group reminiscence therapy programs showed promising effects in improving the depression and meaning of life of older veterans living in veteran homes.  相似文献   
67.
目的探讨专科护士-社区护士-个体-家庭四方联动防跌护理模式在社区跌倒高危老年人中的应用与效果。方法选取深圳市龙岗区的2个社区,随机分为观察组和对照组,从两个社区登记建档的跌倒高风险老年居民中分别随机抽选45名进行干预。观察组采用"专科护士-社区护士-个体-家庭"四方联动推进的综合干预方案。对照组接受社区防跌倒常规护理。于干预前及干预后12个月使用修订版社区老年人跌倒危险评估量表、步态和平衡测试量表对两组老年人进行评测,记录两组1年内跌倒发生例次。结果干预期间跌倒发生情况:观察组1人次,对照组6人次。观察组步态和平衡测试得分提高,跌倒危险评估表得分降低,与对照组比较,差异有统计学意义(均P0.01)。结论四方联动的综合干预方案应用于社区居家老年人,能有效降低老年人跌倒风险,提升其防跌能力,对预防社区老年人跌倒的发生有积极作用。  相似文献   
68.
目的:探讨益胃汤加味对改善原发性干燥综合征(primary sj?rgren's syndrome,pSS)气阴两虚、瘀血阻络证患者疲劳症状及免疫学指标的治疗效果。方法:将116例原发性干燥综合征患者按照随机、对照、单盲法分为治疗组与对照组,每组58例。治疗组给予益胃汤加味方,每日1剂,2次/d;对照组给予硫酸羟氯喹200 mg/次,2次/d,两组均连续治疗24周。比较治疗前后两组患者中医证候疗效、中医疲劳症状积分、疲劳症状视觉模拟评分(visual analogue scale,VAS)以及类风湿因子(rheumatoid factor,RF)与血清免疫球蛋白G(immunoglobulin G,IgG)水平。结果:治疗后治疗组患者中医证候疗效优于对照组(Z=3. 712,P0. 05);治疗组中医疲劳积分与疲劳症状视觉模拟评分改善均优于对照组(P0. 05)。治疗6个月后,治疗组IgG水平较本组治疗前明显下降(P0. 05),与对照组组间比较差异无统计学意义。治疗后两组类风湿因子与本组治疗前比较均无明显下降。治疗组不良反应率1. 75%(1/57),对照组不良反应发生率为25. 49%(13/51)。结论:与硫酸羟氯喹相比,益胃汤加味方治疗pSS,可明显改善患者疲劳及总体症状,两者均可降低血清IgG,益胃汤加味方组疗效较硫酸羟氯喹更明显。两组药物对pSS患者RF水平均无明显影响。长期用药,益胃汤加味方治疗pSS较硫酸羟氯喹更为安全。  相似文献   
69.
Chondrosarcoma is the second most common form of bone cancer and is characterized by its ability to produce an extracellular matrix of the cartilage. High-grade chondrosarcoma is highly aggressive and can metastasize to other parts of the body. Chondrosarcoma is resistant to both conventional chemotherapy and radiotherapy; hence, the current main treatment is still surgical resection. Doxorubicin (Dox) has been shown to significantly improve patient survival compared with untreated chondrosarcoma. However, for patients with metastasis, surgical resection alone can hardly treat them. In addition, drug resistance is one of the leading causes of death in patients with chondrosarcoma. Secreted proteins can mediate cell-cell interactions in the cancer microenvironment, which may be associated with the development of drug resistance. In the present study, chondrosarcoma cells were treated with Dox, the conditioned medium was then collected and changes in secreted proteins were analyzed using the antibody array. Results showed that the Dox-treated group had the highest secretion of basic fibroblast growth factor (bFGF), indicating the effect of bFGF on Dox sensitivity in chondrosarcoma. Furthermore, lentiviral-mediated knockdown and treatment of exogenous recombinant protein were employed to further investigate the effect of bFGF on Dox resistance. Results demonstrated that bFGF can promote the expression of X-ray repair cross-complementing protein 5 (XRCC5), leading to Dox resistance. Secreted bFGF is likely to be detected in serum, in addition to being a biomarker for predicting Dox resistance, the combination of Dox and bFGF/XRCC5 blockers may be a new therapeutic strategy to improve the efficacy of Dox in future.  相似文献   
70.
目的:验证自行设计加工的磁锚定装置在减戳孔腹腔镜阑尾切除术中应用的可行性。方法:设计加工适用于辅助减戳孔腹腔镜阑尾切除术的磁锚定装置,该装置包括内置抓钳和锚定磁体2个部分。以6只健康雄性Beagle犬为模型,用磁锚定装置代替传统腹腔镜阑尾切除术中的副操作孔抓钳,经主操作孔置入磁锚定内置抓钳并钳夹于阑尾尖部,体外放置锚定磁体,锚定磁体与内置抓钳的靶磁体相吸,移动锚定磁体即可改变内置抓钳的牵拉方向,从而有效牵拉暴露手术术野,完成减戳孔腹腔镜阑尾切除手术。记录手术操作时间、术中出血量,评价利用磁锚定装置进行阑尾切除时操作的安全性和可行性。结果:6只Beagle犬均顺利完成磁锚定技术辅助减戳孔腹腔镜阑尾切除,手术时间27~38 min,出血量均小于10 ml,术后实验犬状态良好,未出现并发症。结论:磁锚定装置用于减戳孔腹腔镜阑尾切除手术操作简单、安全可行,在相关设计进一步优化基础上,可尝试或试验性用于临床。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号